Literature DB >> 30188543

Alnylam launches era of RNAi drugs.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30188543     DOI： 10.1038/nbt0918-777

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  Sangamo's lead zinc-finger therapy flops in diabetic neuropathy.

Authors:  Michael Eisenstein
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

2.  Alnylam terminates revusiran program, stock plunges.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2016-12-07       Impact factor: 54.908

3.  Reversal of siRNA-mediated gene silencing in vivo.

Authors:  Ivan Zlatev; Adam Castoreno; Christopher R Brown; June Qin; Scott Waldron; Mark K Schlegel; Rohan Degaonkar; Svetlana Shulga-Morskaya; Huilei Xu; Swati Gupta; Shigeo Matsuda; Akin Akinc; Kallanthottathil G Rajeev; Muthiah Manoharan; Martin A Maier; Vasant Jadhav
Journal:  Nat Biotechnol       Date:  2018-05-14       Impact factor: 54.908

4.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

5.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Authors:  Merrill D Benson; Márcia Waddington-Cruz; John L Berk; Michael Polydefkis; Peter J Dyck; Annabel K Wang; Violaine Planté-Bordeneuve; Fabio A Barroso; Giampaolo Merlini; Laura Obici; Morton Scheinberg; Thomas H Brannagan; William J Litchy; Carol Whelan; Brian M Drachman; David Adams; Stephen B Heitner; Isabel Conceição; Hartmut H Schmidt; Giuseppe Vita; Josep M Campistol; Josep Gamez; Peter D Gorevic; Edward Gane; Amil M Shah; Scott D Solomon; Brett P Monia; Steven G Hughes; T Jesse Kwoh; Bradley W McEvoy; Shiangtung W Jung; Brenda F Baker; Elizabeth J Ackermann; Morie A Gertz; Teresa Coelho
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

6.  2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF.

Authors:  Wen Shen; Xue-Hai Liang; Hong Sun; Stanley T Crooke
Journal:  Nucleic Acids Res       Date:  2015-04-08       Impact factor: 16.971

7.  Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity.

Authors:  Maja M Janas; Mark K Schlegel; Carole E Harbison; Vedat O Yilmaz; Yongfeng Jiang; Rubina Parmar; Ivan Zlatev; Adam Castoreno; Huilei Xu; Svetlana Shulga-Morskaya; Kallanthottathil G Rajeev; Muthiah Manoharan; Natalie D Keirstead; Martin A Maier; Vasant Jadhav
Journal:  Nat Commun       Date:  2018-02-19       Impact factor: 14.919
  7 in total
  44 in total

Review 1.  Strategies, design, and chemistry in siRNA delivery systems.

Authors:  Yizhou Dong; Daniel J Siegwart; Daniel G Anderson
Journal:  Adv Drug Deliv Rev       Date:  2019-05-15       Impact factor: 15.470

2.  Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.

Authors:  Zhen Zheng; Zhefeng Li; Congcong Xu; Bin Guo; Peixuan Guo
Journal:  J Control Release       Date:  2019-08-22       Impact factor: 9.776

Review 3.  Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.

Authors:  Alvin J Mukalel; Rachel S Riley; Rui Zhang; Michael J Mitchell
Journal:  Cancer Lett       Date:  2019-05-14       Impact factor: 8.679

4.  Synthesis and Biological Activity of Short Interfering RNAs Having Several Consecutive Amide Internucleoside Linkages.

Authors:  Venubabu Kotikam; Julien A Viel; Eriks Rozners
Journal:  Chemistry       Date:  2019-12-17       Impact factor: 5.236

5.  Engineering of Solid Dosage Forms of siRNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles Using a Quality-by-Design Approach.

Authors:  Abhijeet Lokras; Camilla Foged; Aneesh Thakur
Journal:  Methods Mol Biol       Date:  2021

6.  Endocytosis Controls siRNA Efficiency: Implications for siRNA Delivery Vehicle Design and Cell-Specific Targeting.

Authors:  Daniel Vocelle; Christina Chan; S Patrick Walton
Journal:  Nucleic Acid Ther       Date:  2019-11-12       Impact factor: 5.486

7.  Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Authors:  Yazhe Wang; Ying Xie; Kameron V Kilchrist; Jing Li; Craig L Duvall; David Oupický
Journal:  ACS Appl Mater Interfaces       Date:  2020-01-15       Impact factor: 9.229

8.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

9.  Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.

Authors:  Hui Shi; Shuo Sun; Haoyue Xu; Zongren Zhao; Zhengzhong Han; Jun Jia; Dongmei Wu; Jun Lu; Hongmei Liu; Rutong Yu
Journal:  Int J Nanomedicine       Date:  2020-05-12

10.  Peptide Spiders: Peptide-Polymer Conjugates to Traffic Nucleic Acids.

Authors:  Ester J Kwon; Henry Ko; Sangeeta N Bhatia
Journal:  Mol Pharm       Date:  2020-07-27       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.